Sarepta Therapeutics Inc

Insider sales by Sarepta’s COO and other executives reveal routine portfolio moves amid a volatile stock; investors should focus on pipeline milestones, not the small trades.

Insightful analysis of Sarepta CFO Wong Ryan Ho‑Yan’s recent sales shows routine vesting‑tax trades, not a warning sign, amid strong clinical data and analyst upgrades.

Executive insider buying at Sarepta Therapeutics signals confidence amid a 26% monthly share decline, highlighting potential for pipeline growth and shareholder alignment.